中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota

文献类型:期刊论文

作者Deng, Zhenzhen2,3,4; Wu, Ning2,3; Wang, Jing2,3; Geng, Lihua2,3; Yue, Yang2,3; Wang, Fahe1; Zhang, Quanbin2,3,4
刊名INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
出版日期2021-12-15
卷号193页码:789-798
关键词Fucoidan Metabolic syndrome Gut microbiota
ISSN号0141-8130
DOI10.1016/j.ijbiomac.2021.10.188
通讯作者Zhang, Quanbin(qbzhang@qdio.ac.cn)
英文摘要Metabolic syndrome (MetS) is a pathological condition of a variety of metabolic abnormalities, which requires more urgent treatment and intervention. Fucoidan has been recommended as a supplement for health enhancement and disease management. Here, we first propose that the beneficial effect of low molecular weight fucoidan fraction LF2 in regulating metabolic syndrome induced by high-fat diet is similar to that of metformin, in terms of molecular mechanism and gut microbiota. The study found that LF2 significantly reduces fasting blood glucose, enhances insulin sensitivity and restores insulin homeostasis and lipid homeostasis. Moreover, LF2 reduced liver oxidative stress and inflammation, and improved hepatocyte steatosis. To decipher the mechanism behind this therapeutic effect, both the molecular mechanisms and gut microbiota were further analyzed. LF2 inhibited the activation of PI3K-Akt-mTOR axis and decreased the expression of SREBP-1c and PPAR gamma in liver. Interestingly, we found that LF2 and metformin have similar effects on gut microbiota, increasing the proportion of Verrucomicrobia and enriching the abundance of Akkermansia muciniphila, which is beneficial to host health. Collectively, our research clarifies the new application of fucoidan as a functional food for anti-MetS, and provides a new insight for fucoidan to exert systemic therapeutic effects from the perspective of molecular mechanism and gut microbiota.
资助项目Major Scientific & Engineering Projects of Innovation in Shandong Province[2019JZZY010818] ; National Natural Science Fundation of China[42176137] ; STS project of the Chinese Academy of Sciences[KFJSTS-QYZD-195] ; Special Open Fund of Laboratory for Marine Biology and Biotechnology, Qingdao Pilot National Laboratory for Marine Science and Technology[OF2020NO02] ; K.C. Wong Education Foundation, CAS
WOS研究方向Biochemistry & Molecular Biology ; Chemistry ; Polymer Science
语种英语
WOS记录号WOS:000729557700002
出版者ELSEVIER
源URL[http://ir.qdio.ac.cn/handle/337002/177497]  
专题海洋研究所_实验海洋生物学重点实验室
通讯作者Zhang, Quanbin
作者单位1.Qingdao Brightmoon Seaweed Grp Co Ltd, State Key Lab Bioact Seaweed Subst, Qingdao, Peoples R China
2.Chinese Acad Sci, Inst Oceanol, CAS & Shandong Prov Key Lab Expt Marine Biol, Ctr Ocean Mega Sci, Qingdao 266071, Peoples R China
3.Qingdao Natl Lab Marine Sci & Tech, Lab Marine Biol & Biotechnol, Qingdao 266071, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
推荐引用方式
GB/T 7714
Deng, Zhenzhen,Wu, Ning,Wang, Jing,et al. Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,2021,193:789-798.
APA Deng, Zhenzhen.,Wu, Ning.,Wang, Jing.,Geng, Lihua.,Yue, Yang.,...&Zhang, Quanbin.(2021).Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota.INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,193,789-798.
MLA Deng, Zhenzhen,et al."Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota".INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 193(2021):789-798.

入库方式: OAI收割

来源:海洋研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。